Amgen's Legacy in Cardiovascular Disease Care: From Breakthrough Science to Real-World Impact
ByAinvest
Wednesday, Oct 1, 2025 4:15 pm ET1min read
AMGN--
Amgen's Repatha, a PCSK9 inhibitor, was developed to help lower LDL-C levels in patients with primary hyperlipidemia, including familial hypercholesterolemia, and reduce the risk of cardiovascular events. Over 57,000 patients have been studied in 51 clinical trials, demonstrating significant LDL-C lowering and cardiovascular risk reduction. Repatha was approved by the US FDA in 2015, providing a new therapeutic option for patients who struggled to reach their LDL-C goals.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet